Semaglu­tide, tirzepatide com­pounder hit with FDA warn­ing let­ter 

Com­pound­ing fa­cil­i­ty ProRx Phar­ma­cy Net­work has re­ceived an FDA warn­ing let­ter over is­sues with its semaglu­tide and tirzepatide pro­duc­tion.

The FDA un­cov­ered sev­er­al is­sues at …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER